Cumberland Delays Ifetroban DMD Extension Data, Sets No New Timeline

Cumberland Pharmaceuticals is a Nashville-based specialty pharmaceutical company that completed a fundamental restructuring on July 1, 2026, when it sold its entire portfolio of FDA-approved commercial brands — Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ — to an affiliate of Apotex Inc. for $100 million in cash, plus an additional $11 million for inventory and transition services. The transaction was approved by more than 99% of voting shares at a June 24, 2026 special meeting. Days after closing, Cumberland's board declared a $1.50-per-share special cash dividend, paid July 31, 2026, to shareholders of record as of July 23, 2026.

Those actions transformed Cumberland from a commercial specialty pharma company — which generated $44.5 million in revenue in 2025 — into a development-stage biopharmaceutical organization. Continuing-operations revenue in Q2 2026 was $166,458, and the company posted a net loss from continuing operations of $3.1 million for the quarter. Before the Apotex proceeds arrived, cash on hand was $3.9 million as of June 30, 2026, though management stated the company would retain significant liquidity following the dividend payout.

The company's pipeline centers on ifetroban, a thromboxane receptor antagonist being evaluated across four Phase 2 programs: DMD-related cardiomyopathy (the FIGHT DMD program), Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and cancer metastasis prevention. The DMD program is the most advanced, with Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the FDA, and documented Phase 2 efficacy data. Cumberland has been conducting end-of-Phase 2 discussions with the FDA regarding remaining development requirements.